Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase III study of Roche's taspoglutide in type 2 diabetes meets primary endpoint

May 3, 2010

Novel SAPK1/JNK1 inhibitors identified by U.S. researchers

May 3, 2010

New company LipimetiX created to focus on lipid-lowering treatments

April 30, 2010

Diamyd Medical continues phase III trials of Diamyd in diabetes

April 29, 2010

BioCryst reports on phase IIa trial of BCX-4208 in patients with gout

April 29, 2010

Phase II data presented on pasireotide in Cushing's disease and acromegaly

April 29, 2010

Living Cell Technologies receives grant from JDRF for phase II DiabeCell trial

April 28, 2010

Santaris advances SPC-5001 into development to lower cholesterol

April 28, 2010

No endocrine safety concerns noted in phase II trials of ulipristal acetate for uterine fibroids

April 28, 2010

Greater HbA1c reductions with LY-2189265 in Hispanic patients with type 2 diabetes

April 28, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...